期刊文献+

联合应用多西他赛治疗激素非依赖性前列腺癌疗效比较的系统评价

A Systematic Review of the Effectiveness of Docetaxel-based Combination for the Treatment of Metastatic Hormone-independent Prostate Cancer
下载PDF
导出
摘要 目的探究目前治疗激素非依赖前列腺癌的最佳化疗方案。方法收集国内外2004年1月至2011年3月已公开发表的有关联用多西他赛治疗激素非依赖前列腺癌疗效比较的临床随机对照试验文献,对符合要求的文献进行归纳分析。结果联合应用多西他赛与泼尼松的化疗方案治疗激素非依赖前列腺癌明显优于对照组。结论联合应用多西他赛与泼尼松的化疗方案治疗激素非依赖前列腺癌,能够控制患者血浆前列腺特异抗原水平,延长患者中位生存期,提高患者生活质量。 Objective To find the best chemotherapy solution of docetaxel-based combination in the treatment of hormone-independent prostate cancer in the current.Methods Literatures about docetaxel-based combination chemotherapy in the treatment of hormone-independent prostate cancer,which is limited to clinical randomized controlled trials,from January 2004 to March 2011 at home and abroad were collected,and the results meeting the requirements were analyzed.Results Combined chemotherapy of docetaxel and prednisone as the treatment of hormone-independent prostate cancer is more effective than the control group.Conclusion In the treatment for hormone-independent prostate cancer,the combination of docetaxel and prednisone can control the PSA levels in the plasma,extend median survival time and improve the patient′s quality of life.
出处 《医学综述》 2012年第3期446-448,共3页 Medical Recapitulate
关键词 多西他赛 激素非依赖性 前列腺癌 系统评价 Docetaxel Hormone-independent Prostate cancer Systematic review
  • 相关文献

参考文献14

  • 1叶定伟,孙燕.激素抵抗性前列腺癌的治疗进展[J].中国癌症杂志,2007,17(3):220-224. 被引量:9
  • 2Matsumoto A,Inoue A,Yokoi S,et al.Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer[J].Int J Urol,2009,16(8):687-691.
  • 3王于勇(综述),郑祥毅(综述),谢立平(审校).激素抵抗性前列腺癌的治疗新进展[J].国际泌尿系统杂志,2007,27(6):754-756. 被引量:3
  • 4李天庆,王剑松.联合多西紫杉醇治疗非激素依赖性前列腺癌临床进展[J].中华男科学杂志,2008,14(3):264-267. 被引量:5
  • 5Tannock IF,de Wit R,Berry WR,et al.Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer[J].N Engl J Med,2004,351(15):1502-1512.
  • 6Petrylak DP,Tangen CM,Hussain MH,et al.Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer[J].N Engl J Med,2004,351(15):1513-1520.
  • 7Oudard S,Banu E,Beuzeboc P,et al.Multicenter randomized phase Ⅱ study of two schedules of docetaxel,estramustine,and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer[J].J Clin Oncol,2005,23(15):3343-3351.
  • 8叶定伟,张海梁,姚旭东,张世林,戴波,沈益君,朱耀,朱一平,陈羽,夏峥嵘.多西他赛联合泼尼松或米托蒽醌联合泼尼松治疗激素抵抗性前列腺癌[J].中国癌症杂志,2007,17(3):236-239. 被引量:19
  • 9Eymard JC,Priou F,Zannetti A,et al.Randomized phase Ⅱ study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer[J].Ann Oncol,2007,18(6):1064-1070.
  • 10Caffo O,Sava T,Comploj E,et al.Docetaxel with or without estramustine phosphate,as first-line chemotherapy for hormone-refractory prostate cancer:results of a multicentre,randomized phase Ⅱ trial[J].BJU Int,2008,102(9):1080-1085.

二级参考文献43

共引文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部